Page 1

AILERON Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update May 11 , 2021 • Progressing ALRN - 6924 : on track to initiate Phase 1b randomized placebo - controlled trial in patients with p53 - mutated non - small cell lung cancer in 2nd quarter 2021 with early interim read - out expected at end of 2021 • ALRN - 6924 is designed to deliver selective chemoprotection against chemotherapy - induced toxicities via p53 biomarker strategy • 50 % of all cancer patients across multiple tumor types have a p53 mutation • Abstract co - authored with Foundation Medicine evaluating frequency of longitudinal changes in TP53 mutation status accepted for presentation at 2021 ASCO Annual Meeting • Aileron to host KOL Fireside Chat moderated by Soumit Roy , Ph.D. , Vice President , Healthcare Analyst with Jones Trading , on May 26 , 2021 • Event will feature renowned hematologist Alan List , M.D. and prominent geriatric oncologist Lodovico Balducci , M.D. BOSTON , May 11 , 2021 ( GLOBE NEWSWIRE ) -- Aileron Therapeutics ( NASDAQ : ALRN ) , a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients , today reported business highlights and financial results for the first quarter ended March 31 , 2021 . " We continue to work diligently to initiate our first randomized , double - blind , placebo - controlled clinical trial of ALRN - 6924 as a novel therapeutic to protect non - small cell lung cancer ( NSCLC ) patients receiving first - line chemotherapy against various chemotherapy - induced toxicities . Approximately 50 % of NSCLC patients have a p53 mutation , suggesting the broad potential impact of ALRN - 6924 in this indication alone , " said Manuel Aivado , M.D. , Ph.D. , President and Chief Executive Officer . Dr. Aivado further commented , " Simultaneously , we are actively planning for the rapid advancement of ALRN - 6924 into late - stage development for patients with p53 - mutated NSCLC pending the outcome of the Phase 1b trial . Bolstered by our successful capital raises in the first quarter of 2021 , we are making near - term strategic investments in CMC , p53 companion diagnostic development , and team scale - up which we expect will not only enable the future advancement of our NSCLC clinical program , but also will provide foundational support for future clinical programs of ALRN - 6924 across multiple p53 - mutated cancer indications . " Aileron is developing ALRN - 6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations , which are present in over half of all cancer patients , to reduce or eliminate chemotherapy - induced side effects while not interfering with chemotherapy's attack on cancer cells . This novel concept is known as chemoprotection . By reducing or eliminating multiple chemotherapy - induced side effects , ALRN - 6924 may improve patients ' quality of life and help them better tolerate chemotherapy . Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy as a result . Given Aileron's p53 biomarker approach , designed to ensure selective chemoprotection only in healthy cells , coupled with the high prevalence of p53 - mutated cancers , the company's strategy is to ultimately pursue a tumor - agnostic label for ALRN - 6924 as a chemoprotective agent in p53 - mutated cancers . First Quarter 2021 Highlights and Recent Updates • Aileron to host upcoming KOL Fireside Chat , " Protecting Cancer Patients from Chemotherapy - Induced Toxicities -